<DOC>
	<DOCNO>NCT00546130</DOCNO>
	<brief_summary>The purpose study examine whether set test group cisplatin + irinotecan + Krestin therapy first-line treatment chemotherapy ( radiotherapy radiotherapy + chemotherapy also allow ) combine Krestin second-line treatment exacerbation compare historical control community control appropriate protocol regimen phase III clinical trial extensive-stage disease ( ED ) small cell lung cancer .</brief_summary>
	<brief_title>Feasibility Study CDDP + CPT-11 + PSK Extensive-Stage Disease ( ED ) Small Cell Lung Cancer</brief_title>
	<detailed_description>To examine whether follow protocol regimen appropriate phase III clinical trial extensive-stage disease ( ED ) small cell lung cancer : set test group cisplatin + irinotecan + Krestin therapy first-line treatment chemotherapy ( radiotherapy radiotherapy + chemotherapy also allow ) combine Krestin second-line treatment exacerbation , evaluate efficacy safety treatment small number case , compare historical control community control .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients histologically cytologically proven small cell lung cancer Patients receive chemotherapy first time Patients indication radical radiotherapy surgical resection Patients diagnose ED* full staging [ chest X ray , chest C , brain CT MRI , abdominal CT abdominal ultrasonography , whole body bone scintigraphy ( may replace PET/CT ) ] ED : Patient distant metastasis include contralateral hilar lymph node metastasis , ipsilateral pleural effusion without distant metastasis exclude . Patients lesion measurable evaluable RECIST criterion Patients age 20 year 75 year Patients preserve organ function indicate follow test value ( data obtain within 14 day prior registration ) Hemoglobin : ≥9.0 g/dL White blood cell count : ≥4,000/mm3 , ≤12,000 /mm3 Neutrophil count : ≥ 2,000/mm3 Platelet count : ≥100,000 /mm3 GOT , GPT : 2.5 time upper limit normal range individual facility Total bilirubin : ≤1.5 mg/dL Serum creatinine : low limit normal range individual facility Creatinine clearance : ≥ 60mL/min Arterial oxygen tension （PaO2） : ≥60 torr ( rest ) Performance status ( PS ) : 01 Absence serious concurrent cardiac pulmonary disease Patients expect survive least 3 month Patients write informed consent obtain Patients serious infection serious complication ( include gastrointestinal bleeding diarrhea ) Patients pleural effusion , ascites , pericardial effusion require treatment include puncture drainage intracavity administration Patients show definite interstitial pneumonitis pulmonary fibrosis plain chest radiograph Patients manifest central nervous system symptom due brain metastasis registration Patients active multiple cancer Patients undergone bone marrow transplantation Patients undergone peripheral blood stem cell transplantation Patients history definite drug allergy Pregnant nursing patient , patient may pregnant intend become pregnant Male patient reproductive capacity intention contraception clinical trial Patients poorly control diabetes Patients administer Krestin past Others : patient judge investigator subinvestigator unsuitable subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>ED-SCLC</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>CPT-11</keyword>
	<keyword>irinotecan hydrochloride</keyword>
	<keyword>CDDP</keyword>
	<keyword>cisplatin</keyword>
	<keyword>PSK</keyword>
	<keyword>Krestin</keyword>
</DOC>